{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:07:13Z","timestamp":1787317633938,"version":"build-2736575974"},"reference-count":16,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Health Science Reports"],"published-print":{"date-parts":[[2021,9]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Spironolactone is an effective treatment for female patients with acne vulgaris. However, topical spironolactone could be a valuable treatment option in both male and female acne patients due to the less possibility of systemic side effects with its topical formulation.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the efficacy and safety of 5% spironolactone cream in the treatment of mild to moderate acne vulgaris.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n In this pilot clinical trial, topical spironolactone 5% was evaluated to treat patients with mild to moderate acne twice a day for 8\u2009weeks. The rate of improvement as any alterations in the number of open and closed comedones, facial inflammatory papules, and acne global grading scores were assessed. Moreover, skin biometric characteristics including skin hydration, erythema, transepidermal water loss (TEWL), pH, sebum, and\n Propionibacterium acnes<\/jats:italic>\n bacteria activity were also assessed following the treatment.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Fifteen patients participated in our study with a mean age of 25\u2009\u00b1\u20094.87\u2009years old. A total of 66.6% (\n n<\/jats:italic>\n \u00a0=\u200910) were female and 33.4% (\n n<\/jats:italic>\n \u00a0=\u20095) were male. The number of acne papules, open and closed comedones, and acne global grading score decreased significantly 4 and 8\u2009weeks after the beginning of treatment (\n P<\/jats:italic>\n \u00a0<\u2009.05). No considerable side effect was reported. Moreover, there was no significant difference between the skin hydration, melanin, erythema, TEWL, pH index, sebum, and\n P acnes<\/jats:italic>\n bacteria activity before, 4, and 8\u2009weeks after the treatment with topical spironolactone cream (\n P<\/jats:italic>\n \u00a0>\u2009.05).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n The topical 5% spironolactone cream seems to be an effective and safe treatment of acne vulgaris in both male and female patients.<\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/hsr2.317","type":"journal-article","created":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T00:38:01Z","timestamp":1625186281000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy and safety of topical spironolactone 5% cream in the treatment of acne: A pilot study"],"prefix":"10.1002","volume":"4","author":[{"given":"Azin","family":"Ayatollahi","sequence":"first","affiliation":[{"name":"Center for Research and Training in Skin Diseases and Leprosy Tehran University of Medical Sciences Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0134-429X","authenticated-orcid":false,"given":"Ansieh","family":"Samadi","sequence":"additional","affiliation":[{"name":"Center for Research and Training in Skin Diseases and Leprosy Tehran University of Medical Sciences Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayda","family":"Bahmanjahromi","sequence":"additional","affiliation":[{"name":"Skin Research Center Shahid Beheshti University of Medical Sciences Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7947-8642","authenticated-orcid":false,"given":"Reza M.","family":"Robati","sequence":"additional","affiliation":[{"name":"Skin Research Center Shahid Beheshti University of Medical Sciences Tehran Iran"},{"name":"Department of Dermatology Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,7]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60321-8"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.11.021"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14374"},{"key":"e_1_2_10_5_1","first-page":"740","article-title":"Acne vulgaris: treatment guidelines from the AAD","volume":"95","author":"Croke LM","year":"2017","journal-title":"Am Fam Physician"},{"key":"e_1_2_10_6_1","first-page":"37","article-title":"Oral spironolactone in post\u2010teenage female patients with acne vulgaris: practical considerations for the clinician based on current data and clinical experience","volume":"5","author":"Kim GK","year":"2012","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.09.024"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8019.2006.00077.x"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.4668"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2016.05.042"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12010025"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03350151"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.1996.tb04006.x"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1986.tb02807.x"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2010.488260"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12185"},{"key":"e_1_2_10_17_1","first-page":"193","article-title":"Experience in the therapy of acne with topical administration of spironolactone as an antiandrogen","volume":"135","author":"Califano L","year":"1990","journal-title":"Clin Ter"}],"container-title":["Health Science Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hsr2.317","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hsr2.317","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hsr2.317","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T04:16:30Z","timestamp":1693282590000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hsr2.317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1002\/hsr2.317"],"URL":"https:\/\/doi.org\/10.1002\/hsr2.317","archive":["Portico"],"relation":{},"ISSN":["2398-8835","2398-8835"],"issn-type":[{"value":"2398-8835","type":"print"},{"value":"2398-8835","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"2021-02-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e317"}}